- Home
- SOPH vs CDXS Comparison
SOPH vs CDXS Comparison
Compare SOPH & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPH
- CDXS
- Stock Information
- Founded
- SOPH 2011
- CDXS 2002
- Country
- SOPH Switzerland
- CDXS United States
- Employees
- SOPH N/A
- CDXS N/A
- Industry
- SOPH Biotechnology: Biological Products (No Diagnostic Substances)
- CDXS Major Chemicals
- Sector
- SOPH Health Care
- CDXS Industrials
- Exchange
- SOPH Nasdaq
- CDXS Nasdaq
- Market Cap
- SOPH 231.8M
- CDXS 216.6M
- IPO Year
- SOPH 2021
- CDXS 2010
- Fundamental
- Price
- SOPH $5.00
- CDXS $2.37
- Analyst Decision
- SOPH
- CDXS Buy
- Analyst Count
- SOPH 0
- CDXS 2
- Target Price
- SOPH N/A
- CDXS $11.00
- AVG Volume (30 Days)
- SOPH 143.5K
- CDXS 623.1K
- Earning Date
- SOPH 11-04-2025
- CDXS 11-06-2025
- Dividend Yield
- SOPH N/A
- CDXS N/A
- EPS Growth
- SOPH N/A
- CDXS N/A
- EPS
- SOPH N/A
- CDXS N/A
- Revenue
- SOPH $69,688,000.00
- CDXS $57,164,000.00
- Revenue This Year
- SOPH $16.60
- CDXS $12.88
- Revenue Next Year
- SOPH $19.09
- CDXS $21.64
- P/E Ratio
- SOPH N/A
- CDXS N/A
- Revenue Growth
- SOPH 7.32
- CDXS N/A
- 52 Week Low
- SOPH $2.58
- CDXS $1.90
- 52 Week High
- SOPH $5.30
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- SOPH 63.97
- CDXS 40.13
- Support Level
- SOPH $4.01
- CDXS $2.52
- Resistance Level
- SOPH $4.36
- CDXS $2.80
- Average True Range (ATR)
- SOPH 0.39
- CDXS 0.15
- MACD
- SOPH 0.05
- CDXS -0.03
- Stochastic Oscillator
- SOPH 80.65
- CDXS 12.24
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.